Warren RB, Blauvelt A, Poulin Y, Beeck S, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial. Br J Dermatol 2020 Jun 28. doi: 10.1111/bjd.19341.
PMID: 32594522